Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: culler md. FASEB J. 2017 Nov;31(11):4682-4696. doi: 10.1096/fj.201601264RRR. Epub 2017 Jul 13. FASEB J. 2017. PMID: 28705809
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP. Durán-Prado M, et al. Among authors: culler md. J Clin Endocrinol Metab. 2010 May;95(5):2497-502. doi: 10.1210/jc.2009-2247. Epub 2010 Mar 16. J Clin Endocrinol Metab. 2010. PMID: 20233783
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Luque RM, et al. Among authors: culler md. Cancer Lett. 2015 Apr 10;359(2):299-306. doi: 10.1016/j.canlet.2015.01.037. Epub 2015 Jan 28. Cancer Lett. 2015. PMID: 25637790 Free PMC article.
Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Sampedro-Núñez M, et al. Among authors: culler md. Oncotarget. 2016 Feb 9;7(6):6593-608. doi: 10.18632/oncotarget.6565. Oncotarget. 2016. PMID: 26673010 Free PMC article. Clinical Trial.
The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP. Gahete MD, et al. Among authors: culler md. Oncotarget. 2016 Sep 13;7(37):60110-60122. doi: 10.18632/oncotarget.11076. Oncotarget. 2016. PMID: 27507050 Free PMC article.
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: culler md. Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9. Mol Cancer. 2017. PMID: 28851363 Free PMC article.
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.
Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japón MA, Barrera-Martín A, Vasiljevic A, Hill J, Zhang S, Halem H, Solivera J, Raverot G, Gálvez MA, Soto-Moreno A, Paez-Pereda M, Culler MD, Castaño JP, Luque RM. Vázquez-Borrego MC, et al. Among authors: culler md. Clin Cancer Res. 2020 Feb 15;26(4):957-969. doi: 10.1158/1078-0432.CCR-19-2154. Epub 2019 Oct 17. Clin Cancer Res. 2020. PMID: 31624102
The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
Puig-Domingo M, Luque RM, Reverter JL, López-Sánchez LM, Gahete MD, Culler MD, Díaz-Soto G, Lomeña F, Squarcia M, Mate JL, Mora M, Fernández-Cruz L, Vidal O, Alastrué A, Balibrea J, Halperin I, Mauricio D, Castaño JP. Puig-Domingo M, et al. Among authors: culler md. PLoS One. 2014 Jan 21;9(1):e85527. doi: 10.1371/journal.pone.0085527. eCollection 2014. PLoS One. 2014. PMID: 24465589 Free PMC article.
In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.
Ibáñez-Costa A, Gahete MD, Rivero-Cortés E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA, Venegas-Moreno E, Gálvez MÁ, García-Arnés JA, Soto-Moreno A, Morgan J, Tsomaia N, Culler MD, Dieguez C, Castaño JP, Luque RM. Ibáñez-Costa A, et al. Among authors: culler md. Sci Rep. 2015 Mar 4;5:8714. doi: 10.1038/srep08714. Sci Rep. 2015. PMID: 25737012 Free PMC article.
In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
Luque RM, Sampedro-Nuñez M, Gahete MD, Ramos-Levi A, Ibáñez-Costa A, Rivero-Cortés E, Serrano-Somavilla A, Adrados M, Culler MD, Castaño JP, Marazuela M. Luque RM, et al. Among authors: culler md. Oncotarget. 2015 Aug 14;6(23):19619-33. doi: 10.18632/oncotarget.4316. Oncotarget. 2015. PMID: 26124083 Free PMC article.
188 results